Molecular Cancer Therapeutics

Table of Contents

September 2014 • Volume 13 • Number 9

Highlights of This Issue 2139

REVIEW

2141 Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
Clémence Feneyrolles, Aurélie Spenlinhauer, Léa Guiet, Bénédicte Fauvel, Bénédicte Daydé-Cazals, Pierre Warnault, Gwénaël Chevé, and Aziz Yasri

SMALL MOLECULE THERAPEUTICS

2149 Direct Inhibition of Choline Kinase by a Near-Infrared Fluorescent Carbocyanine
Sean P. Arlauckas, Anatoliy V. Popov, and Edward J. Delikatny

2159 Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
Anaïs Balbous, Brigitte Renoux, Ulrich Cortes, Serge Milin, Karline Guilloteau, Thibaut Legigan, Pierre Rivet, Odile Boissonnade, Sébastien Martin, Caroline Tripiana, Michel Wager, René Jean Bensadoun, Sébastien Papot, and Lucie Karayan-Tapon

2170 Translational Exposure-Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)

LARGE MOLECULE THERAPEUTICS

2194 EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein
Dmitrij Hristodorov, Manal Amoury, Radoslav Mladenov, Judith Niesen, Katharina Arens, Nina Berges, Lea Hein, Stefano Di Fiore, Anh-Tuan Pham, Michael Huhn, Wijnand Helfrich, Rainer Fischer, Theo Thepen, and Stefan Barth

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2203 Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-kB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, and George R. Stark

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

2215 Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
Naoki Mine, Sayaka Yamamoto, Donald W. Kufe, Daniel D. Von Hoff, and Takumi Kawabe

2226 Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
Ana Custodio, Juan Moreno-Rubio, Jorge Aparicio, Javier Gallego-Plazas, Ricardo Yaya, Joaín Maurel, Nuria Rodríguez-Salas, Emilio Burgos, David Ramos, Ana Calatrava, Encarna Andrade, Esther Díaz-López, Antonio Sánchez, Rosario Madero, Paloma Cejas, and Jaime Feliu

2238 Epidermal Growth Factor–like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer
Torben Frostrup Hansen, Boye Schnack Nielsen, Flemming Brandt Sørensen, Anders Johnsson, and Anders Jakobsen
CORRECTIONS

2246 Correction: Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models

2248 Correction: Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death

ABOUT THE COVER

To elucidate the potential mode of action of MAP-based cytolytic fusion proteins in living cells, colocalization assays were performed using EGFR⁺ A549 cells transfected with a SNAP-tagged tubulin DNA construct. Expressed SNAP-tagged tubulin molecules were labeled with SNAP-Cell TMR-Star (green). EGF-MAPf151 was used as a representative for MAP-based CFPs. MAPf151 was detected using mouse–anti-human Tau and goat–anti-mouse Alexa Fluor 647 antibodies (red). DAPI was used to counterstain the nucleus (blue). Using confocal fluorescence microscopy and a tubulin polymerization assay, it could be shown that MAP colocalized with and stabilized microtubules. For more details, see article by Hristodorov and colleagues on page 2194.